APPENDIX

eTable 1. Target Daily Doses of Medications with Demonstrated Efficacy in AMI

Medication	Target Dose	Trial Demonstrating Efficacy
Beta Blockers		
Atenolol	100 mg	ISIS-1 (1986)(1)
Metoprolol	200 mg	Hjalmarson et al. (1981)(2), Lopressor Intervention Trial (1987)(3)
Carvedilol	50 mg	CAPRICORN (2001)(4)
Propranolol	180 mg	Beta Blocker Heart Attack Trial (1982)(5)
Angiotensin Converting Enzyme Inhibitors		
Captopril	150 mg	SAVE study (1992)(6)
Enalopril	20 mg	CONSENSUS II (1992)(7), SOLVD-Prevention (1992)(8), SOLVD-Treatment (1991)(9)
Fosinopril	40 mg	FEST (1995)(10), FAMIS (1998)(11)
Lisinopril	20 mg	GISSI-3 (1994)(12); ATLAS (1999)(13)
Perindopril	8 mg	EUROPA (2003)(14)
Quinapril	20 mg	QUIET (2001)(15)
Ramipril	10 mg	AIRE (1993)(16)
Trandolapril	4 mg	TRACE (1995)(17)
Angiotensin II Receptor Blockers		
Candesartan	32 mg	CHARM-Alternative (2003)(18)
Telmisartan	80 mg	ONTARGET (2008)(19)
Valsartan	320 mg	VALIANT (2003)(20)

All beta-blocker and statin trials and the majority of ACE/ARB trials were acute therapy studies, wherein the medication was started during the acute phase of the AMI and target dose was attempted during hospitalization (50% of acute therapy trials) or within 4 weeks of discharge. In the few chronic therapy trials, target dose attainment was attempted within 4 weeks of initiation.

eTable 2. Mean Achieved Doses in the Trials Demonstrating Efficacy for AMI

Clinical Trial	Medication	Target Dose	Mean Achieved Dose (% of target)	% Achieving Target Dose
ISIS-1	Atenolol	100 mg	79 mg (79%)	66%
CAPRICORN	Carvedilol	50 mg	40 mg (80%)	
Beta Blocker Heart Attack Trial	Propranolol	180 mg	191 mg (106%)*	
SAVE	Captopril	150 mg		79%
CONSENSUS 2	Enalopril	20 mg		82%
FAMIS	Fosinopril	20 mg	18.3 mg (92%)	87%
EUROPA	Perindopril	8 mg	7.7 mg (96%)	
CHARM-Alternative	Candesartan	32 mg		72%
ONTARGET	Telmisartan	80 mg		89%
VALIANT	Valsartan	320 mg		77%

*Patients were allowed to be on 180 mg or 240 mg

eTable 3. Statin Dose Categories According to Potency

	Medication					
Dose	**Atorvastatin**	**Fluvastatin**	**Lovastatin**	**Pravastatin**	**Rosuvastatin**	**Simvastatin**
Low	10 mg	10-40 mg	10-20mg	10-20 mg	5 mg	10-20mg
Moderate	20 mg	80 mg	40 mg	40 mg	10mg	40mg
Goal*	40-80mg		80 mg	80 mg	20-40mg	80 mg

*Goal is considered ≥75% of maximal statin potency (~50-60% LDL reduction)

eTable 4. Medication Dose Strength at Hospital Discharge and Follow-up. A medication was considered at goal if the dose was at least 75% of the target dose (i.e., dose with proven efficacy from clinical trials). A dose that was 50-74% of target was considered moderate, whereas doses below 50% of target were considered low.

Beta-blockers	**Follow-up Dose Category**					
Discharge Dose	**None**	**On Med/No Titrate**	**Low**	**Moderate**	**Goal**	**Total**
None	112	18	55	23	21	229
On Med/No Titrate	217	498	0	0	31	746
Low	506	0	761	255	81	1603
Moderate	186	0	143	307	64	700
Goal	138	27	63	103	201	532
Total	1159	543	1022	688	398	3810
Statins	**Follow-up Dose Category**					
	None		**Low**	**Moderate**	**Goal**	**Total**
None	331		83	99	66	579
Low	281		420	201	76	978
Moderate	498		119	713	239	1569
Goal	528		49	185	848	1610
Total	1638		671	1198	1229	4736
ACE/ARBs	**Follow-up Dose Category**					
Discharge Dose	**None**	**On Med/No Titrate**	**Low**	**Moderate**	**Goal**	**Total**
None	31	7	5	6	10	59
On Med/No Titrate	45	60	0	0	15	120
Low	44	0	31	9	16	100
Moderate	30	0	7	36	31	104
Goal	51	8	3	4	80	146
Total	201	75	46	55	152	529

Patients on medication but with SBP <110 mmHg were excluded from the up-titration analyses

Follow-up dose is lower than discharge dose

Follow-up dose is the same than discharge dose

Follow-up dose is higher than discharge dose (i.e., up-titration)

eFigure 1. Outpatient Cardiology Follow-up Intensity







eTable 5. Patient and Treatment Factors Associated with Goal Dose at Follow-up. Sensitivity Analyses

	Beta Blocker		Statin		ACE/ARB	
	OR (95% CI)	**p-value**	**OR (95% CI)**	**p-value**	**OR (95% CI)**	**p-value**
Dose at discharge			**MAIN ANALYSES**			
Low dose	**0.50 (0.30-0.83)**	**0.008**	**0.67 (0.47-0.95)**	**0.024**	0.86 (0.34-2.15)	0.748
Moderate dose	0.93 (0.55-1.59)	0.799	**1.36 (1.01-1.82)**	**0.043**	1.83 (0.78-4.27)	0.162
Goal dose	**6.08 (3.70-10.01)**	**<0.001**	**8.22 (6.20-10.90)**	**<0.001**	**5.80 (2.56-13.16)**	**<0.001**
Dose at discharge			**ADDING DISCHARGE LDL-C LEVELS**			
Low dose	NA		**0.67 (0.47-0.95)**	**0.025**	NA	
Moderate dose	NA		1.34 (1.00-1.81)	0.051	NA	
Goal dose	NA		**8.03 (6.05-10.65)**	**<0.001**	NA	
Dose at discharge	**LIMITING ANALYSES TO PATIENTS WITHOUT LV DYSFUNCTION**					
Low dose	**0.50 (0.30-0.83)**	**0.007**	NA		NA	
Moderate dose	0.93 (0.54-1.57)	0.774	NA		NA	
Goal dose	**5.94 (3.62-9.75)**	**<0.001**	NA		NA	

REFERENCES FOR APPENDIX

1. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57-66.
2. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;2:823-7.
3. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Lopressor Intervention Trial Research Group. Eur Heart J 1987;8:1056-64.
4. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
5. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 1982;247:1707-14.
6. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
7. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
8. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992;327:685-91.
9. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293-302.
10. Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J 1995;16:1892-9.
11. Borghi C, Marino P, Zardini P, Magnani B, Collatina S, Ambrosioni E. Short- and long-term effects of early fosinopril administration in patients with acute anterior myocardial infarction undergoing intravenous thrombolysis: results from the Fosinopril in Acute Myocardial Infarction Study. FAMIS Working Party. Am Heart J 1998;136:213-25.
12. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115-22.
13. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-8.
14. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.

15. Pitt B, O'Neill B, Feldman R, et al. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am J Cardiol 2001;87:1058-63.
16. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993;342:821-8.
17. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-6.
18. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
19. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
20. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.